Are there enough data to consider temozolomide plus PARP inhibitor in ES-SCLC after progression on chemo-immunotherapy and lurbinectedin, in the absence of a clinical trial?

Community
Company
News
Contact Us
Sign in

Topics: Thoracic Malignancies • Medical Oncology • Small cell lung cancer

Several studies have evaluated the regimen though with differing PARP inhibitors and temozolomide doses.

Related Questions

Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?

How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?

What is your approach to isolated thoracic recurrence of NSCLC in an otherwise asymptomatic patient with prior chemoradiation and immunotherapy?

How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?

Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?

Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?

What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?

For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?

How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?

What factors would determine which currently approved agent to use as a first line treatment for a stage IV ROS-1 fusion patient with the approval of repotrectinib?